Diamond Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
6
Diamond Therapeutics General Information
Description
Operator of a drug development company intended to work towards new and suitable therapies for mental health conditions by unlocking the promise of psychedelic compounds. The company offers healthcare services like psychopharmacology, biotechnology, life sciences, and neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines, focused on safe, take-at-home treatments that hold potential for use across a broad patient cohort -maximizing the positive impact useful drugs can have on global mental health, enabling patients to deliver current first-line treatments and recover faster.
Contact Information
Website
www.diamondthera.comCorporate Office
- 410 Adelaide Street West
- Suite 220
- Toronto, Ontario M5V 1S8
- Canada
Corporate Office
- 410 Adelaide Street West
- Suite 220
- Toronto, Ontario M5V 1S8
- Canada
Diamond Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Diamond Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Diamond Therapeutics Patents
Diamond Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026156439-A1 | Tetrahydro-5h-pyrazino[2,3-d]azepines as novel 5-ht2a and/or 5-ht2c receptor agonists for therapeutic treatment | Pending | 23-Jan-2025 | ||
| EP-4536671-A1 | Amorphous (a-polymorphic) psilocybin | Pending | 09-Jun-2022 | ||
| EP-4536671-A4 | Amorphous (a-polymorphic) psilocybin | Pending | 09-Jun-2022 | ||
| US-12590110-B2 | Amorphous (a-polymorphic) psilocybin | Active | 09-Jun-2022 | ||
| US-20240360161-A1 | Amorphous (a-polymorphic) psilocybin | Active | 09-Jun-2022 | C07F9/5728 |
Diamond Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Diamond Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Diamond Therapeutics FAQs
-
When was Diamond Therapeutics founded?
Diamond Therapeutics was founded in 2018.
-
Where is Diamond Therapeutics headquartered?
Diamond Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Diamond Therapeutics?
Diamond Therapeutics has 8 total employees.
-
What industry is Diamond Therapeutics in?
Diamond Therapeutics’s primary industry is Drug Discovery.
-
Is Diamond Therapeutics a private or public company?
Diamond Therapeutics is a Private company.
-
What is Diamond Therapeutics’s current revenue?
The current revenue for Diamond Therapeutics is .
-
Who are Diamond Therapeutics’s investors?
Pacific Reach Capital, First Avenue Ventures, Ontario Brain Institute, Ambria Capital, and JLS Fund are 5 of 10 investors who have invested in Diamond Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
